Cobra Biologics and Recopharma have signed an agreement to supply a human Fc fusion protein. Cobra will apply its maxXpress platform service to deliver a program of vector construction using UCOE technology, transfectant pool generation, and supply, purification and protein characterization. The service allows Recopharma to form a quick and reliable assessment on the specific expertise of Cobra’s cell line development and analytical scientist teams, according to a joint statement. Recopharma ha...